Apr 22, 2008 - Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced completion of enrollment in NB-301, the largest of its Phase III clinical trials, for Contrave(R), its lead obesity product candidate. This represents completion of enrollment in the second of four Phase III trials of Contrave. The NB-301 clinical trial is a placebo-controlled, 56-week study intended to analyze the efficacy, safety and tolerability of two doses of Contrave in generally healthy obese patients. This trial is taking place at 34 centers nationwide and has randomized approximately 1742 patients... Orexigen's Press Release -
